Organic Payment Gateways, a leading provider of specialized payment solutions, proudly announces the launch of its easily integrated payment gateway and merchant account program. This program is ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

PATIENTS taking blockbuster diabetes and weight loss drugs are waking up with vision loss, researchers warn. Some reported ...

Pursuing dangerous Medicaid block grant schemes and allowing flagrant violations of unequivocal state laws looks like ...

The Trump administration has promised that addressing childhood obesity will be a key part of its “Make America Healthy Again ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...

The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...

Big pharma’s pushing for PBS funding, and it’s kickstarting a shift to healthier snacks, smaller portions, and more ...

Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper savings to outdo his predecessor.

Telehealth provider Hims & Hers Health is defending its planned Super Bowl ad, which is styled as a political manifesto ...